Market Overview

UPDATE: Deutsche Bank Downgrades IPC The Hospitalist Company to Hold Following Q2 Results

Related IPCM
IPC Hires New Senior Vice President of Sales And Marketing
IPC Issues Response Following DoJ Complaint, Says Related to Reimbursement Claims

In a report published Friday, Deutsche Bank analyst Darren Lehrich downgraded the rating on IPC The Hospitalist Company (NASDAQ: IPCM) from Buy to Hold, but reiterated the $48.00 price target.

In the report, Deutsche Bank noted, “IPCM's Q2 results were slightly below expectations due primarily to a sequential deceleration in encounter (volume) growth and flattish yoy margins. While 13.5% revenue and EBITDA growth is respectable, we believe IPCM's forward trading multiple (20.5x P/E and 11.4x EV/EBITDA) demands slightly more, and thus an earnings miss with decelerating fundamental trends seems disappointing. While we expect IPCM's EPS growth to track 14-15% over the next 24 months, we believe decelerating encounter growth (due to weaker hospital census and modestly higher physician turnover) poses some risk to the story. Moving to Hold on a more balanced risk/reward equation.”

IPC The Hospitalist Company closed on Thursday at $52.12.

Posted-In: Darren Lehrich Deutsche BankAnalyst Color Downgrades Analyst Ratings


Most Popular

Related Articles (IPCM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters